Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Pernix Therapeutics Holdings Inc Issues FY 2013 Revenue Guidance Below Analysts' Estimates


Friday, 10 May 2013 08:02am EDT 

Pernix Therapeutics Holdings Inc announced that it expects net revenues of Pernix, with the addition of the Cypress/Hawthorn, and Somaxon product portfolios, to be in the range of $90 to $100 million for fiscal 2013. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $124 million for fiscal 2013. 

Company Quote

8.49
0.32 +3.92%
25 Jul 2014